Gene Editing: Increasing demand for use of genetically modified crops, prevalence of Alzheimer’s disease, dementia, infectious diseases, and cancer will drive the growth of market at a CAGR of 20.93% during forecasted period.

Market Research Future (MRFR) has published a cooked research report on the “global gene editing market” that contains the information from 2023 to 2030. The gene editing market is estimated to register a CAGR of 20.93% during the forecast period of 2023 to 2030.

MRFR recognizes the following companies as the key players in the global gene editing market— GE Healthcare (US), Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories, Inc (US), Lonza (Switzerland), GenScript (US), Horizon Discovery Ltd (UK), OriGene Technologies, Inc (US), Integrated DNA Technologies, Inc (US), New England Biolabs, Inc (US), Sangamo Therapeutics (US) and others.

Market Highlights

The global gene editing market is accounted for to register a CAGR of 20.93% during the forecast period and is estimated to reach USD 27.21 billion by 2030.

The single largest growth trend is increasing funding for genetic research. The market space witnesses rising evolution of genetic engineering across the globe. Thus, the growing number of strategic initiatives in the market space. One such key growth factor promoting an exponential increase in Year on Year (%) growth due to the increasing use in pharmaceutical and biotechnology industry.

Furthermore, rising prevention and treatment of human diseases, genome editing is of tremendous interest, increase in geriatric population that are propel the growth of gene editing market. However, stringent government regulations are expected to hamper the growth of the global market. Nevertheless, the growing research and development activity is projected to create lucrative opportunity pockets for market players. We estimate a more focused business initiates targeting the same would result in greater revenue pockets for market players.

Segment Analysis

The global gene editing market is segmented into technology, application, end user, and region.

Based on technology, the market is segmented into CRISPR, TALEN, ZFN, Antisense, and others. The CRISPR segment was attributed to holding the largest market share in 2022 with a market share of ~36.0% as estimated by MRFR analysts.

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is the largest and fastest-growing segment, owing to its wide range of applications in vivo to fix the target gene and ex vivo to rewire & redirect cells for genetic diseases and immuno-oncology autoimmune diseases. Moreover, the major players include AbbVie, Inc. (US), Novartis AG (Switzerland), Bristol Myers Squibb Company (US), Sanofi (France), Vertex Pharmaceuticals Incorporated (US), Regeneron Pharmaceuticals, Inc. (US), and Biogen, Inc. (US). These companies are indulged and highly active in developing CRISPR-based therapeutic products for genetic diseases.

Further, we estimate that the market segment will continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet to witness continuous innovations and movements in terms of new products launches. 

Based on application, the global gene editing market has been segmented into genetic engineering, gene therapy, cell line engineering, and others. The gene therapy segment held the largest market share in 2022.

Further, based on the end user, the market is segmented into biotechnology and pharmaceutical companies, contract research organizations (CROs), and academic & government research institutes. The biotechnology and pharmaceutical companies’ segment is projected to have the largest market share during the forecast period.

Explore In-depth Details: Gene Editing Market Research Report

Regional Analysis

The global gene editing market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.

The global gene editing market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe gene editing market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The gene editing market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World gene editing market comprises of Middle East, Africa, and Latin America.

The imperative factors, such as the rising prevalence of cancer and other genetic disorders, a growing preference for personalized medicine, an increase in private and public sector funding, and rapid advancements in sequencing and gene editing technologies are driving the market for gene editing in the North America region, are boosting the growth of the North America region.

Moreover, the Europe market has been persistently growing owing to factors such as technological advancements in healthcare IT such as the use of Artificial intelligence (AI) to manufacture CRISPR systems are driving growth. Developers in the healthcare IT industry are responsible for analyzing procedures to control and monitor all phases of product development. The focus is on developing technologies ranging from biomarker discovery to clinical trials and patient monitoring.

Additionally, with market factors, such as the growth in the rising prevalence of cancer and other genetic abnormalities. Japan continues to see significant growth in terms of CRISPR technology innovation are driving the Asia-Pacific region’s growth.

Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The market factors such as growing government support, rising public-private partnerships, and increased funding are all contributing to the region's biotechnology industry's growth.

Key Findings of the Study

• The global clinical laboratory service market is expected to reach USD 27.21 billion by 2030, at a CAGR of 20.93% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, the rising prevalence of cancer and other genetic abnormalities, increasing research and development activity drive the growth of gene editing market in Asia-Pacific region.


• Based on technology, the CRISPR segment was attributed to holding the largest market in 2022, with an approximate market share of XX%.


• GE Healthcare (US), Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories, Inc (US), Lonza (Switzerland), GenScript (US), Horizon Discovery Ltd (UK), OriGene Technologies, Inc (US), Integrated DNA Technologies, Inc (US), New England Biolabs, Inc (US), Sangamo Therapeutics (US)